Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol

• Published in: Expert opinion on drug metabolism & toxicology Vol. 12; no. 6; pp. 669 - 680
• Main Authors: Franken, L. G., de Winter, B. C. M, van Esch, H. J., van Zuylen, L., Baar, F. P. M., Tibboel, D., Mathôt, R. A. A., van Gelder, T., Koch, B. C. P.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.06.2016
• Subjects: Analgesics, Opioid - administration & dosage; Analgesics, Opioid - pharmacokinetics; Animals; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - pharmacokinetics; Haloperidol; Haloperidol - administration & dosage; Haloperidol - pharmacokinetics; Humans; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - pharmacokinetics; midazolam; Midazolam - administration & dosage; Midazolam - pharmacokinetics; morphine; Morphine - administration & dosage; Morphine - pharmacokinetics; palliative care; Palliative Care - methods; pharmacokinetics; Quality of Life; Terminal Care - methods; terminal illness; pharmacokinetics; Haloperidol; terminal illness; midazolam; palliative care; morphine
• ISSN: 1742-5255; 1744-7607
• DOI: 10.1080/17425255.2016.1179281

Introduction: A variety of medications are used for symptom control in palliative care, such as morphine, midazolam and haloperidol. The pharmacokinetics of these drugs may be altered in these patients as a result of physiological changes that occur at the end stage of life. Areas covered: This review gives an overview of how the pharmacokinetics in terminally ill patients may differ from the average population and discusses the effect of terminal illness on each of the four pharmacokinetic processes absorption, distribution, metabolism, and elimination. Specific considerations are also given for three commonly prescribed drugs in palliative care: morphine, midazolam and haloperidol). Expert opinion: The pharmacokinetics of drugs in terminally ill patients can be complex and limited evidence exists on guided drug use in this population. To improve the quality of life of these patients, more knowledge and more pharmacokinetic/pharmacodynamics studies in terminally ill patients are needed to develop individualised dosing guidelines. Until then knowledge of pharmacokinetics and the physiological changes that occur in the final days of life can provide a base for dosing adjustments that will improve the quality of life of terminally ill patients. As the interaction of drugs with the physiology of dying is complex, pharmacological treatment is probably best assessed in a multi-disciplinary setting and the advice of a pharmacist, or clinical pharmacologist, is highly recommended.